Bifogade filer
PDF
Kurs
+14,60%
Likviditet
0,25 MSEK
Kalender
| Est. tid* | ||
| 2026-03-03 | 08:30 | Bokslutskommuniké 2025 |
| 2025-11-04 | 08:30 | Kvartalsrapport 2025-Q3 |
| 2025-08-12 | 08:30 | Kvartalsrapport 2025-Q2 |
| 2025-05-14 | N/A | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
| 2025-05-13 | N/A | Årsstämma |
| 2025-05-06 | 08:30 | Kvartalsrapport 2025-Q1 |
| 2025-03-04 | - | Bokslutskommuniké 2024 |
| 2024-11-05 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-13 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-15 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
| 2024-05-14 | - | Årsstämma |
| 2024-05-07 | - | Kvartalsrapport 2024-Q1 |
| 2024-03-05 | - | Bokslutskommuniké 2023 |
| 2023-10-17 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-15 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-25 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-17 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
| 2023-05-16 | - | Årsstämma |
| 2023-03-07 | - | Bokslutskommuniké 2022 |
| 2022-11-22 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-16 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-25 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
| 2022-05-24 | - | Årsstämma |
| 2022-05-03 | - | Kvartalsrapport 2022-Q1 |
| 2022-03-08 | - | Bokslutskommuniké 2021 |
| 2021-11-02 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-17 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-25 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
| 2021-05-24 | - | Årsstämma |
| 2021-05-04 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-08 | - | Bokslutskommuniké 2020 |
| 2020-11-11 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-18 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-20 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
| 2020-05-19 | - | Årsstämma |
| 2020-05-13 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-12 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-12 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-09 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
| 2019-05-08 | - | Årsstämma |
| 2019-05-08 | - | Kvartalsrapport 2019-Q1 |
| 2019-03-19 | - | Extra Bolagsstämma 2019 |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
| 2018-11-15 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-15 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-15 | - | Extra Bolagsstämma 2018 |
| 2018-05-15 | - | Kvartalsrapport 2018-Q1 |
| 2018-03-01 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
| 2018-02-28 | - | Årsstämma |
| 2018-01-30 | - | Bokslutskommuniké 2017 |
| 2017-05-31 | - | Extra Bolagsstämma 2017 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Scandinavian ChemoTech's Animal Care continues its momentum, achieving an order intake exceeding USD 230,000 (2.3 MSEK) in Q1 2025 which makes it the best quarter so far in regards of sales. This reinforces the steady growth in revenue observed in previous quarters, signaling a positive long-term trend toward profitability.
A key factor behind this success is the increasing recognition of the clinical and financial benefits of TSE treatments. Customer satisfaction remains a cornerstone of our growth, with clients expressing appreciation for both the effectiveness of our technology and the high level of service we provide.
"To start the year with such a strong first quarter is truly encouraging and sets a positive tone for the months ahead," says Ann Ohlsson, Head of Finance at Scandinavian ChemoTech and VQ Animal Care. "Even with this solid performance, we see our pipeline expanding-not only in terms of business opportunities but also in the speed at which they materialize. Consistently increasing our revenues quarter by quarter strengthens our confidence in our forecasts and long-term potential."
With this strong start to 2025 and an accelerating demand for our innovative veterinary solutions, Animal Care is well-positioned for continued success. The company remains focused on sustainable growth, bringing the group closer to its first profitable quarter sooner than anticipated.
This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 01-04-2025 09:15 CET.
For further information please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se
Certified Adviser: Redeye AB, Phone: +46 (0)8 - 121 576 90
E-mail: certifiedadviser@redeye.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.